SCHEMBL6715688

SCHEMBL6715688

Cc1cccc(Cl)c1NC(=O)C(N)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 1/20 0.51
HSP90AA1 P07900 1/20 0.49
ATM Q13315 1/20 0.49
GAA P10253 1/20 0.49
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
PYGL P06737 6/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTGS2 P35354 1/20 0.45
CHRNA7 P36544 1/20 0.45
LCK P06239 2/20 0.44
MAPK14 Q16539 1/20 0.44
ROCK2 O75116 1/20 0.44
CDC42 P60953 1/20 0.44
ROCK1 Q13464 1/20 0.44
PKN2 Q16513 1/20 0.44
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714089 0.90 ATM (0.55) CXCL8HSP90AA1ATMGAACYP3A4
SCHEMBL6715723 0.82 MEN1 (0.55) CXCL8HSP90AA1ATMGAAPDK1
SCHEMBL6727017 0.82 ALDH1A1 (0.59) HSP90AA1ATMPTGS2
SCHEMBL6717218 0.82 MAPK1 (0.50) CXCL8HSP90AA1ATMCYP3A4CYP2C19
SCHEMBL12780367 0.79 CXCL8 (0.58) CXCL8HSP90AA1ATMGAAPDK1
SCHEMBL11402399 0.78 PDK1 (0.59) CXCL8GAAPDK1PDK2PDK3
SCHEMBL6718773 0.77 RAB9A (0.55) GAACYP3A4CYP2C19
SCHEMBL6718687 0.77 RAB9A (0.55) GAACYP3A4CYP2C19
SCHEMBL28609335 0.77 RAB9A (0.55) GAACYP3A4CYP2C19
SCHEMBL6719505 0.77 KCNQ2 (0.61) GAACYP2C19ROCK2CDC42ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 CXCL8 3916/4885HSP90AA1 1837/4885ATM 3390/4885
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 CXCL8 3808/4885HSP90AA1 1673/4885ATM 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.